Document Actions
UCLA Nano Startup Starts Trials on Wireless Body Monitor
MediSens Wireless, a startup company within UCLA's high-tech incubator for nanotechnology, has received the OK to start clinical trials of its novel wireless body-monitoring system, which is designed to assess muscle and neuromotor functions.
CMAS consists of a clinical assessment instrument and associated software designed to help the healthcare professional to evaluate and capture current and ongoing muscle and neuro-motor functions.
The device could assist medical professionals with early diagnosis of degenerative disease, as well as better follow in-home and telemedicine patients.
MediSens, supported by UCLA’s California NanoSystems Institute, has approval under Food and Drug Administration guidelines to begin testing its Clinical Movement Assessment System (CMAS) for use in a wide variety of medical applications for physical medicine, rehabilitation, neurology, orthopedics, and physical and occupational therapy, among others, according to CMAS development team.
Founded in 2007, MediSens is the first spinout from the UCLA Wireless Health Institute.
The team hopes CMAS will provide clinical assessments of fine motor movement, gross muscle strength, hand-eye coordination and patient response to treatment. Closely captured repeat assessments will lead to early warning and detection of deteriorating conditions.
"Data gathered by CMAS, has the potential to enable health care professionals to improve care through early intervention and better tracking of outcomes and response to treatment," said Dr. Jay Rindenau, M.D., the company's chief medical officer. CMAS was co-invented by Reggie Edgerton, Ph.D., a professor of neurophysiology at UCLA.
CMAS consists of a clinical assessment device and associated software that will allow health care providers to capture current and ongoing muscle and neuromotor functions, thereby providing them with quantifiable, real-time data for their decision-making.
CMAS could also have further uses, including help diagnose degenerative diseases such as Parkinson's,
Clinical trials under Food and Drug Administration guidelines are planned for community hospitals, public health facilities, and the Ronald Reagan UCLA Medical Center. The success of the trial will be evaluated by the efficacy and cost effectiveness of the system in testing early interventions for better outcomes and long-term patient care.
The California NanoSystems Institute
The California NanoSystems Institute at UCLA is an integrated research center operating jointly at UCLA and UC Santa Barbara whose mission is to foster interdisciplinary collaborations for discoveries in nanosystems and nanotechnology; train the next generation of scientists, educators and technology leaders; and facilitate partnerships with between academia and industry. The CNSI was established in 2000 with $100 million from the state of California and an additional $250 million in federal research grants and industry funding.
MediSens moved to the new CNSI incubator in 2009 to begin commercializing licensed technology originally invented by a team led by Majid Sarrafzadeh, a UCLA professor of computer science and engineering and co-director of the Wireless Health Institute at UCLA. The company's mission is to design and deliver personal medical monitoring systems that advance human health.
MediSens, supported by UCLA’s California NanoSystems Institute, has approval under Food and Drug Administration guidelines to begin testing its Clinical Movement Assessment System (CMAS) for use in a wide variety of medical applications for physical medicine, rehabilitation, neurology, orthopedics, and physical and occupational therapy, among others, according to CMAS development team.
Founded in 2007, MediSens is the first spinout from the UCLA Wireless Health Institute.
The team hopes CMAS will provide clinical assessments of fine motor movement, gross muscle strength, hand-eye coordination and patient response to treatment. Closely captured repeat assessments will lead to early warning and detection of deteriorating conditions.
"Data gathered by CMAS, has the potential to enable health care professionals to improve care through early intervention and better tracking of outcomes and response to treatment," said Dr. Jay Rindenau, M.D., the company's chief medical officer. CMAS was co-invented by Reggie Edgerton, Ph.D., a professor of neurophysiology at UCLA.
CMAS consists of a clinical assessment device and associated software that will allow health care providers to capture current and ongoing muscle and neuromotor functions, thereby providing them with quantifiable, real-time data for their decision-making.
CMAS could also have further uses, including help diagnose degenerative diseases such as Parkinson's,
Clinical trials under Food and Drug Administration guidelines are planned for community hospitals, public health facilities, and the Ronald Reagan UCLA Medical Center. The success of the trial will be evaluated by the efficacy and cost effectiveness of the system in testing early interventions for better outcomes and long-term patient care.
- The first phase of the trial will deal with baseline evaluations and therapeutic exercise.
- The second phase will involve an in-depth analysis of different sensory-motor pathways.
The California NanoSystems Institute
The California NanoSystems Institute at UCLA is an integrated research center operating jointly at UCLA and UC Santa Barbara whose mission is to foster interdisciplinary collaborations for discoveries in nanosystems and nanotechnology; train the next generation of scientists, educators and technology leaders; and facilitate partnerships with between academia and industry. The CNSI was established in 2000 with $100 million from the state of California and an additional $250 million in federal research grants and industry funding.
MediSens moved to the new CNSI incubator in 2009 to begin commercializing licensed technology originally invented by a team led by Majid Sarrafzadeh, a UCLA professor of computer science and engineering and co-director of the Wireless Health Institute at UCLA. The company's mission is to design and deliver personal medical monitoring systems that advance human health.